Endo International (NASDAQ:ENDP) (TSE:ENL) was upgraded by research analysts at BidaskClub from a “hold” rating to a “buy” rating in a report issued on Thursday.

Other equities analysts have also issued research reports about the company. Zacks Investment Research upgraded Endo International from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a research note on Thursday, January 17th. Canaccord Genuity set a $17.00 price target on Endo International and gave the company a “buy” rating in a research note on Friday, March 8th. SunTrust Banks started coverage on Endo International in a research note on Tuesday. They issued a “buy” rating and a $13.00 price target on the stock. TheStreet lowered Endo International from a “c-” rating to a “d+” rating in a research note on Tuesday, November 27th. Finally, Piper Jaffray Companies reiterated a “hold” rating on shares of Endo International in a research note on Friday, March 1st. Fourteen research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Endo International has a consensus rating of “Hold” and an average target price of $15.44.

Endo International stock opened at $8.73 on Thursday. Endo International has a one year low of $5.27 and a one year high of $18.50. The firm has a market cap of $1.93 billion, a price-to-earnings ratio of 3.02 and a beta of 1.21.

Endo International (NASDAQ:ENDP) (TSE:ENL) last issued its quarterly earnings results on Thursday, February 28th. The company reported $0.75 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.59 by $0.16. Endo International had a negative return on equity of 337.13% and a negative net margin of 35.00%. During the same period last year, the business posted $0.77 EPS. On average, equities analysts forecast that Endo International will post 2.17 earnings per share for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. LS Investment Advisors LLC acquired a new stake in shares of Endo International during the 4th quarter valued at $59,000. Oregon Public Employees Retirement Fund acquired a new stake in shares of Endo International during the 4th quarter valued at $76,000. First Quadrant L P CA acquired a new stake in shares of Endo International during the 4th quarter valued at $92,000. Neuburgh Advisers LLC boosted its holdings in shares of Endo International by 13.9% during the 4th quarter. Neuburgh Advisers LLC now owns 24,860 shares of the company’s stock valued at $181,000 after acquiring an additional 3,036 shares in the last quarter. Finally, Neuberger Berman Group LLC acquired a new stake in shares of Endo International during the 3rd quarter valued at $202,000. 92.40% of the stock is currently owned by institutional investors.

About Endo International

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Featured Story: How prevalent are 12b-1 fees?

Analyst Recommendations for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.